Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697473 | 0.90 | BLM (0.48) | BLMCYP2D6SMN1; SMN2ALDH1A1TBXA2R | |
| SCHEMBL4872782 | 0.80 | L3MBTL1 (0.47) | BLMCYP2D6SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL5515476 | 0.70 | LTB4R (0.54) | SMN1; SMN2ALDH1A1TBXA2RHDAC3MAPK1 | |
| SCHEMBL25345484 | 0.70 | BLM (0.38) | BLMCYP2D6SMN1; SMN2ALDH1A1TBXA2R | |
| SCHEMBL5522710 | 0.69 | LTB4R (0.55) | SMN1; SMN2ALDH1A1TBXA2RPPARA | |
| SCHEMBL4869921 | 0.69 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1CYP1A2CYP2C19ALOX15 | |
| SCHEMBL21827762 | 0.69 | L3MBTL1 (0.39) | BLMCYP2D6SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL3673389 | 0.68 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1HDAC3MAPK1ADRA1A | |
| SCHEMBL6687222 | 0.68 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1HDAC3MAPK1ADRA1A | |
| Adipic Acid SCHEMBL29198027 | 0.68 | NOS3 (0.59) | SMN1; SMN2ALDH1A1TBXA2RL3MBTL1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395290-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | claimed |
| WO-2002094325-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-11-28 | — | — | WO | claimed |
| US-7361347-B2 | Cytotoxic CD44 antibody immunoconjugates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-22 | — | — | US | disclosed |
| US-20050271672-A1 | Cytotoxic CD44 antibody immunoconjugates | ADOLF GUENTHER | 2005-12-08 | — | — | US | disclosed |
| EP-1531869-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING MAYTANSINOID CD44 ANTIBODY IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2005-05-25 | — | — | EP | disclosed |
| US-20040126379-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| US-20040120949-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| WO-2004041307-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES AND RADIOTHERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-05-21 | — | — | WO | disclosed |
| EP-1417974-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy | Boehringer Ingelheim International GmbH (DE) | 2004-05-12 | — | — | EP | disclosed |
| EP-1395290-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2004018000-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING MAYTANSINOID CD44 ANTIBODY IMMONOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
| EP-1391213-A1 | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents | Boehringer Ingelheim International GmbH (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20030103985-A1 | Cytotoxic CD44 antibody immunoconjugates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2002094325-A2 | CYTOTOXIC CD44 ANTIBODY IMMUNOCONJUGATES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050271672-A1 | Cytotoxic CD44 antibody immunoconjugates | CD44, CD47, EPCAM | BLM 4654/4885CYP2D6 2846/4885SMN1; SMN2 2871/4885 |
| US-20040120949-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy | CD44, CD47, EPCAM | BLM 3498/4885CYP2D6 1760/4885SMN1; SMN2 4221/4885 |
| US-20030103985-A1 | Cytotoxic CD44 antibody immunoconjugates | CD44, CD47, EPCAM | BLM 4654/4885CYP2D6 2846/4885SMN1; SMN2 2871/4885 |
| US-20040126379-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents | CD44, EPCAM, FUT4 | BLM 4775/4885CYP2D6 2000/4885SMN1; SMN2 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.